The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 15, 2021

Filed:

Nov. 04, 2016
Applicant:

Neurocrine Biosciences, Inc., San Diego, CA (US);

Inventors:

Nicole Harriott, San Diego, CA (US);

Nicholas Pagano, San Diego, CA (US);

Assignee:

Neurocrine Biosciences, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 211/14 (2006.01); A61K 31/4545 (2006.01); C07D 401/12 (2006.01); C07D 211/40 (2006.01); C07D 211/26 (2006.01); A61P 25/28 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4545 (2013.01); A61K 31/444 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); C07D 211/26 (2013.01); C07D 211/40 (2013.01); C07D 401/12 (2013.01);
Abstract

Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, L, L, R, R, R, R, w, x, y and z are as defined herein. Methods for treating diseases/disorders by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also disclosed. Such diseases/disorders are e.g. neurological diseases/disorders such as e.g. Alzheimer's Disease, Lewy Body Dementia and the cognitive deficits associated with schizophrenia, Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy, progressive supranuclear palsy, and Huntington's disease. Preferred compounds are e.g. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds wherein the pyrazine has been replaced by e.g. pyridazine, pyrimidine, pyridine or phenyl.


Find Patent Forward Citations

Loading…